- $53.79m
- -$2.92m
- $31.06m
- 55
- 43
- 34
- 40
Annual income statement for Enzo Biochem, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2019 July 31st | 2020 July 31st | 2021 July 31st | R2022 July 31st | 2023 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 81.2 | 76 | 118 | 32.6 | 31.1 |
| Cost of Revenue | |||||
| Gross Profit | 23.2 | 23.8 | 53.6 | 13.4 | 11.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 79.4 | 106 | 124 | 49.7 | 55.8 |
| Operating Profit | 1.73 | -30.4 | -6.31 | -17 | -24.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 2.49 | -28.5 | 7.88 | -20.3 | -25 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.49 | -28.5 | 7.88 | -20.3 | -25 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 2.49 | -28.5 | 7.88 | -18.3 | 20.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.49 | -28.5 | 7.88 | -18.3 | 20.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.494 | -0.457 | 0.406 | -0.317 | -0.403 |